AU4208799A - Interleukins-21 and 22 - Google Patents

Interleukins-21 and 22

Info

Publication number
AU4208799A
AU4208799A AU42087/99A AU4208799A AU4208799A AU 4208799 A AU4208799 A AU 4208799A AU 42087/99 A AU42087/99 A AU 42087/99A AU 4208799 A AU4208799 A AU 4208799A AU 4208799 A AU4208799 A AU 4208799A
Authority
AU
Australia
Prior art keywords
interleukins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU42087/99A
Other languages
English (en)
Inventor
Reinhard Ebner
Steven M. Ruben
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of AU4208799A publication Critical patent/AU4208799A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU42087/99A 1998-05-29 1999-05-27 Interleukins-21 and 22 Abandoned AU4208799A (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US8734098P 1998-05-29 1998-05-29
US60087340 1998-05-29
US9980598P 1998-09-10 1998-09-10
US60099805 1998-09-10
US13196599P 1999-04-30 1999-04-30
US60131965 1999-04-30
PCT/US1999/011644 WO1999061617A1 (en) 1998-05-29 1999-05-27 Interleukins-21 and 22

Publications (1)

Publication Number Publication Date
AU4208799A true AU4208799A (en) 1999-12-13

Family

ID=27375658

Family Applications (1)

Application Number Title Priority Date Filing Date
AU42087/99A Abandoned AU4208799A (en) 1998-05-29 1999-05-27 Interleukins-21 and 22

Country Status (6)

Country Link
US (3) US20030003545A1 (enExample)
EP (1) EP1082433A4 (enExample)
JP (1) JP2002516103A (enExample)
AU (1) AU4208799A (enExample)
CA (1) CA2329274A1 (enExample)
WO (1) WO1999061617A1 (enExample)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150090A (en) * 1986-01-09 2000-11-21 Massachusetts Institute Of Technology Nuclear factors associated with transcriptional regulation
US6569645B2 (en) 1999-05-14 2003-05-27 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US6579520B2 (en) 1998-05-15 2003-06-17 Genentech, Inc. IL-17 related mammalian cytokine polypeptides (IL-17E)
US6562578B1 (en) 1999-01-11 2003-05-13 Schering Corporation IL-17-like cytokine binding compounds and antibodies
US7771719B1 (en) 2000-01-11 2010-08-10 Genentech, Inc. Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
EP3112468A1 (en) * 1998-05-15 2017-01-04 Genentech, Inc. Il-17 homologous polypeptides and therapeutic uses thereof
ES2292242T5 (es) 1998-05-15 2011-05-04 Genentech, Inc. Utilizaciones terapéuticas de polipéptidos homólogos de il-17.
US20030220258A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of ischemic events
US20040132136A1 (en) * 1998-09-17 2004-07-08 Zymogenetics, Inc. Mammalian Transforming growth factor beta-9
IL141869A0 (en) 1998-09-17 2002-03-10 Zymogenetics Inc Mammalian transforming growth factor beta-9 (ztgfss9)
US7081528B2 (en) * 1998-10-26 2006-07-25 Ludwig Institute For Cancer Research Isolated nucleic acid molecules encoding T cell derived inducible factors
US6274710B1 (en) * 1998-10-26 2001-08-14 Ludwig Institute For Cancer Research Antibodies which specifically bind T Cell inducible factors (TIFs)
WO2000042187A1 (en) * 1999-01-11 2000-07-20 Schering Corporation Interleukin-17 related mammalian cytokine (il-171). polynucleotides encoding them. uses
KR20010089764A (ko) * 1999-01-11 2001-10-08 둘락 노먼 씨. 인터류킨-17과 관련된 포유류의 사이토카인, 이를코딩하는 폴리뉴클레오티드 및 이의 용도
US6307024B1 (en) 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
US6939545B2 (en) 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
US7307161B1 (en) 1999-04-28 2007-12-11 Genetics Institute, Llc Human Gil-19/AE289 polynucleotides
JP2016047051A (ja) * 1999-12-23 2016-04-07 ジェネンテック， インコーポレイテッド Ｉｌ−１７相同的ポリペプチドとその治療上の用途
DK1897944T3 (da) * 1999-12-23 2011-10-24 Genentech Inc IL-17 homologe polypeptider og terapeutisk anvendelse deraf
JP2003527104A (ja) * 1999-12-23 2003-09-16 ジェネンテック・インコーポレーテッド Ｉｌ−１７相同的ポリペプチドとその治療上の用途
US20040043397A1 (en) 2000-01-11 2004-03-04 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
TWI238191B (en) * 2000-02-08 2005-08-21 Amgen Inc IL-17 like molecules and uses thereof
US7094566B2 (en) 2000-03-16 2006-08-22 Amgen Inc., IL-17 receptor like molecules and uses thereof
US7718397B2 (en) 2000-03-21 2010-05-18 Genentech, Inc. Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof
EP1300418A1 (en) * 2001-10-04 2003-04-09 Erasmus Universiteit Rotterdam Gene regulation by oligopeptides
ES2317898T3 (es) 2000-04-18 2009-05-01 Schering Corporation Usos medicinales de agonistas y antogonistas de il-174.
US20030096969A1 (en) 2000-06-02 2003-05-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7268223B2 (en) 2000-09-22 2007-09-11 Wyeth Isolated nucleic acid molecules which encode a soluble IL-TIF receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof
US7094570B2 (en) 2003-03-11 2006-08-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode a soluble IL-TIF/IL-22 receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof
EP1326974B1 (en) * 2000-10-13 2006-12-27 Eli Lilly And Company Methods of using a human il-17-related polypeptide to treat disease
ATE501730T1 (de) * 2001-01-25 2011-04-15 Zymogenetics Inc Verfahren zur behandlung von psoriasis unter verwendung eines il-17d antagonisten
US7471042B2 (en) 2001-02-06 2008-12-30 Panasonic Corporation Plasma display panel with an improved electrode
JP2005510451A (ja) * 2001-02-23 2005-04-21 ジェネティクス インスティテュート，エルエルシー 炎症性障害を治療するための組成物及び方法
US7638604B2 (en) 2001-02-23 2009-12-29 Genetics Institute, Llc Monoclonal antibodies against interleukin-22
AU2002367534A1 (en) * 2001-11-06 2003-11-03 Eli Lilly And Company Use of il-19, il-22 and il-24 to treat hematopoietic disorders
US7033787B2 (en) 2001-12-21 2006-04-25 Ludwig Institute For Cancer Research Isolated cytokine receptor LICR-2
US7560433B2 (en) 2001-12-21 2009-07-14 Biotempt B.V. Treatment of multiple sclerosis (MS)
US20080242837A1 (en) * 2001-12-21 2008-10-02 Khan Nisar A Peptide compositions
CA2481304A1 (en) * 2002-03-27 2003-10-09 Patrick Hwu Method for treating cancer in humans
SI1501369T1 (sl) 2002-04-26 2015-10-30 Genentech, Inc. Neafinitetno čiščenje proteinov
WO2004003156A2 (en) * 2002-07-01 2004-01-08 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Il-21 as a regulator of immunoglobin production
WO2004016774A1 (ja) * 2002-08-13 2004-02-26 Kirin Beer Kabushiki Kaisha 抑制性nk細胞受容体陽性細胞の増幅方法
WO2004032953A1 (en) * 2002-10-11 2004-04-22 Novo Nordisk A/S Treatment of allergic conditions by use of il 21
EP1731163A2 (en) * 2002-10-11 2006-12-13 Novo Nordisk A/S Treatment of allergic conditions by use of IL 21
RU2005132458A (ru) * 2003-03-21 2006-03-20 Уайт (Us) Лечение иммунологических расстройств с использованием агонистов интерлейкина-21/рецептора интерлейкина-21
US7517529B2 (en) * 2003-04-08 2009-04-14 Biotempt B.V. Treatment of type I diabetes
DK1641822T3 (da) 2003-07-08 2013-07-22 Genentech Inc Heterologe il-17-a/f-polypeptider og terapeutiske anvendelser deraf.
US7276478B2 (en) * 2003-09-25 2007-10-02 Zymogenetics, Inc. Methods of treating autoimmune diseases using IL-21
DE602004029173D1 (de) * 2003-10-10 2010-10-28 Novo Nordisk As Il-21-derivate
US20060228331A1 (en) 2003-10-10 2006-10-12 Novo Nordisk A/S IL-21 Derivatives and variants
PT1748789E (pt) * 2003-11-05 2011-04-04 Inst Rech Developpement Ird Il-22 para prevenir doenças infecciosas
EP1692276B1 (en) 2003-11-19 2010-07-21 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Method of inducing memory b cell development and terminal differentiation
ATE506433T1 (de) * 2003-12-19 2011-05-15 Novo Nordisk As Prozessierung von peptiden und proteinen
US20060286629A1 (en) 2003-12-19 2006-12-21 Norby Inga S N Processing of Peptides and Proteins
ITRM20040586A1 (it) * 2004-11-29 2005-02-28 Giuliani Spa Epitopi antigenici dell'interleuchina-21, anticorpi relativi e loro uso in campo medico.
AU2006237329B2 (en) 2005-04-18 2012-04-12 Novo Nordisk A/S IL-21 variants
US7675819B2 (en) * 2005-10-17 2010-03-09 The Johns Hopkins University Volumetric passive sonobuoy array of polyvinylidene fluoride (PVDF) wires
US20070122413A1 (en) 2005-11-28 2007-05-31 Sivakumar Pallavur V Il-21 antagonists
WO2007071768A1 (en) * 2005-12-23 2007-06-28 Novo Nordisk A/S Purification of proteins using preparative reverse phase chromatography (rpc)
TWI417301B (zh) 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
TW200744634A (en) 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
EP1864692A1 (en) * 2006-06-07 2007-12-12 Biotempt B.V. Use of peptides for the control of radiation injury
AU2007310777A1 (en) 2006-10-26 2008-05-02 Novo Nordisk A/S IL-21 variants
EP2109620B1 (en) * 2006-12-21 2012-08-22 Novo Nordisk A/S Interleukin-21 variants with altered binding to the il-21 receptor
DK2120991T3 (da) * 2007-02-12 2014-04-28 Biotempt Bv Behandling af traumatisk blødning med korte oligopeptider
US20080217002A1 (en) * 2007-03-07 2008-09-11 Floyd Randolph Simonds Sand control screen having a micro-perforated filtration layer
CN101361968B (zh) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 白介素-22在治疗脂肪肝中的应用
US20090202475A1 (en) * 2007-11-07 2009-08-13 Genentech, Inc. Compositions and methods for treatment of microbial disorders
AU2016259423B2 (en) * 2007-11-07 2018-11-08 Genentech, Inc. Compositions and methods for treatment of microbial disorders
BRPI0908312A2 (pt) 2008-05-05 2015-08-18 Novimmune Sa '' anticorpo monoclonal totalmente humano isolado, composição farmacêutica, método de alívio de um sintoma de uma indicação clínica e método de alívio de um sintoma de uma doença autoimune, distúrbio inflamatório ou distúrbio da proliferação celular''
CN102348463B (zh) * 2009-01-12 2014-05-07 健能隆医药技术（上海）有限公司 白介素-22在预防和/或治疗多器官功能障碍综合症(mods)中的用途
EP2427203B1 (en) 2009-05-05 2018-10-17 Novimmune S.A. Anti-il-17f antibodies and use thereof
CN102380091A (zh) 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 白介素-22在治疗病毒性肝炎中的应用
CN103182072B (zh) * 2011-12-27 2017-05-03 健能隆医药技术（上海）有限公司 白介素‑22在治疗和预防神经损伤疾病或神经退行性疾病中的用途
EP2903634A1 (en) * 2012-10-03 2015-08-12 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for the prophylactic treatment of bacterial superinfections post-influenza
PL2970422T3 (pl) 2013-03-15 2018-09-28 F.Hoffmann-La Roche Ag Polipeptydy IL-22 i białka fuzyjne IL-22 Fc i sposoby zastosowania
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Il-22二聚体在制备静脉注射药物中的应用
US11135268B2 (en) * 2015-07-07 2021-10-05 Fred Hutchinson Cancer Research Center Compositions, kits, and methods using interleukin-17C to promote neural growth and/or neural survival
WO2017181143A1 (en) 2016-04-15 2017-10-19 Generon (Shanghai) Corporation, Ltd. Use of il-22 in treating necrotizing enterocolitis
KR20190141695A (ko) 2017-04-13 2019-12-24 센티 바이오사이언시스, 인코포레이티드 병용 암 면역요법
CA3116138A1 (en) 2018-10-17 2020-04-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
EP4106794A4 (en) 2020-02-19 2024-03-20 Evive Biotechnology (Shanghai) Ltd METHOD FOR TREATING TRANSPLANT AND HOST DISEASE

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242798A (en) * 1983-07-21 1993-09-07 Scripps Clinic And Research Foundation Synthetic polypeptides corresponding to portions of proteinoids translated from brain-specific mRNAs, receptors, methods and diagnostics using the same
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
JPH04218000A (ja) * 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
US5256766A (en) * 1991-02-19 1993-10-26 The Regents Of The University Of California Recombinant thrombin receptor and related pharmaceuticals
EP0708178A1 (en) * 1994-10-19 1996-04-24 Institut National De La Sante Et De La Recherche Medicale (Inserm) Survival motor neuron (SMN) gene: a gene for spinal muscular atrophy
EP0839196B1 (en) * 1995-07-19 2005-05-11 Genetics Institute, LLC Human ctla-8 and uses of ctla-8-related proteins
US20030054442A1 (en) * 1998-05-15 2003-03-20 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US6569645B2 (en) * 1999-05-14 2003-05-27 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US20020177188A1 (en) * 1998-05-15 2002-11-28 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US6579520B2 (en) * 1998-05-15 2003-06-17 Genentech, Inc. IL-17 related mammalian cytokine polypeptides (IL-17E)
US6562578B1 (en) * 1999-01-11 2003-05-13 Schering Corporation IL-17-like cytokine binding compounds and antibodies
ES2292242T5 (es) * 1998-05-15 2011-05-04 Genentech, Inc. Utilizaciones terapéuticas de polipéptidos homólogos de il-17.
US20020182673A1 (en) * 1998-05-15 2002-12-05 Genentech, Inc. IL-17 homologous polypedies and therapeutic uses thereof
US20040132136A1 (en) * 1998-09-17 2004-07-08 Zymogenetics, Inc. Mammalian Transforming growth factor beta-9
US20040043397A1 (en) * 2000-01-11 2004-03-04 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US20030180255A1 (en) * 2000-08-24 2003-09-25 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US20030203451A1 (en) * 2000-08-24 2003-10-30 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US20030096969A1 (en) * 2000-06-02 2003-05-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP2130919A1 (en) * 2001-11-05 2009-12-09 ZymoGenetics, Inc. IL-21 antagonists

Also Published As

Publication number Publication date
JP2002516103A (ja) 2002-06-04
US20030092133A1 (en) 2003-05-15
EP1082433A4 (en) 2003-01-02
US20030003545A1 (en) 2003-01-02
CA2329274A1 (en) 1999-12-02
WO1999061617A1 (en) 1999-12-02
US20070207943A1 (en) 2007-09-06
EP1082433A1 (en) 2001-03-14

Similar Documents

Publication Publication Date Title
AU9790198A (en) Compounds and methods
IL128869A0 (en) Pyrozolopyrimidines and pyrazolotriazines
AU9781998A (en) Huchordin and uses thereof
AU4198299A (en) Compounds and uses thereof
AU2349399A (en) R-lansoprazole compositions and methods
AU3753599A (en) Micro-compartmentalization device and uses thereof
AU2972597A (en) Compositions and uses thereof
AU2660900A (en) 4-haloalkyl-3-heterocyclylpyridines and 4-haloalkyl-5-heterocyclyl-pyrimidines and their use as repellents
PL348668A1 (en) 3,3-biarylpiperidine and 2,2-biarylmorpholine derivatives
AU2592299A (en) Sailboats and methods
AUPP433398A0 (en) Compounds and processes
AU8695298A (en) Compounds and uses thereof
AU2333099A (en) Aryloxyanilides and related compounds
AU3086200A (en) Eyesight-correction and/or eye-training device
AU2980799A (en) Lectomedin materials and methods
AU8693198A (en) Compounds and uses thereof
AU3776495A (en) Aryloxycycloalkenyl and aryloxyiminocycloalkenylhydroxyureas
EP0953510A3 (de) Gefache
AUPP232098A0 (en) Sensacam 101
AUPP662198A0 (en) Stripakote 2000
AU2955699A (en) "mirror-wiper" for truck-motor vehicles and the like
HK1028791A (en) Sel-10 and uses thereof
AUPM938594A0 (en) Smokehood 173
AU4094597A (en) 25-methylene and 24,25-epoxy marcfortines and paraherquamides
AUPO913997A0 (en) Vannexe I and vannexe II

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase